Urotensin II is an inverse predictor of death and fatal cardiovascular events in chronic kidney disease  by Ravani, P. et al.
Urotensin II is an inverse predictor of death and fatal
cardiovascular events in chronic kidney disease
P Ravani1, G Tripepi2, P Pecchini1, F Mallamaci2, F Malberti1 and C Zoccali2
1Divisione di Nefrologia e Dialisi Azienda Istituti Ospitalieri di Cremona, Cremona, Italy and 2CNR – IBIM, Epidemiologia Clinica
e Fisiopatologia delle Malattie Renali e dell’Ipertensione Arteriosa, Reggio Calabria, Italy
Urotensin II (UTN), a cyclic vasoactive peptide expressed in
multiple organs, had higher plasma levels that was
previously shown to predict longer survival in dialysis
patients. We sought to determine if this association exists in
earlier stages of chronic kidney disease (CKD) by studying a
cohort of 122 incident clinically stable pre-dialysis patients.
Linear models were used to determine associations of UTN
with baseline characteristics such as renal function and
traditional and nontraditional cardiovascular risk factors.
We used Cox regression analysis to model time-to-death as a
function of UTN and the same variables for adjustment
including a time-varying covariate that indicated progression
to end-stage renal disease. No correlation was found
between baseline glomerular filtration rate and plasma UTN.
In adjusted analysis, UTN correlated directly with serum
albumin and, inversely, with history of previous coronary
events. During a mean follow-up of 41 months, 43 patients
died – 29 from cardiovascular events. After adjusting for
potential confounding factors, increased UTN predicted
lower risk of death from all-cause and cardiovascular causes.
In patients with moderate-to-severe CKD, plasma UTN was
found to be an inverse predictor of overall and cardiovascular
mortality.
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Urotensin II (UTN) is a highly conserved cyclic undeca-
peptide expressed in disparate species from teleost fish to
mammals.1–3 In humans, UTN is intensely represented in
various organ systems including the nervous system, the
gastrointestinal system, the kidney, and the cardiovascular
system. Interest on this peptide was generated by a series of
observations showing that the plasma concentration and/or
the gene expression at tissue level of UTN is altered in a large
series of diseases including atherosclerosis,1 hypertension,4
cardiac ischemia,5 heart failure,6,7 diabetic nephropathy,8–10
and advanced renal insufficiency.11,12 Although high levels of
this compound are generally considered as potentially
noxious to the heart and the kidney, it is presently unknown
whether high UTN determines adverse clinical outcomes.2
Indeed this peptide emerged as a potentially vasoprotective
substance in some experiments in human vessels in vitro,13
whereas other experimental data indicated that UTN either
does not produce measurable changes in systemic and
peripheral hemodynamics in healthy humans14 or that it
may induce a sustained vasoconstriction in the forearm.15
UTN dilates cutaneous vessels in healthy subjects,16,17
whereas it produces an opposite effect in patients with
hypertension16 and in heart failure.17 Investigating the
implications of UTN, derangements for human health is
recognized as a much challenging problem because experi-
ments performed so far in animal and in vitro models have
shown that the effect of this peptide depends on species,
administration route, vascular bed, organ system, and
physiological or pathophysiological condition.3 At this stage
of knowledge well-conceived prospective studies in patients
with cardiovascular and renal diseases may offer important
interpretative clues for understanding the relationship
between UTN and disease states and to generate scientific
hypotheses to be tested in mechanistic and intervention
studies.
Chronic kidney disease (CKD) represents a useful model
to explore the potential role of UTN in human diseases
because it was shown that the plasma concentration of this
substance is increased both in patients with diabetic
nephropathy and moderate-to-severe renal insufficiency and
in patients with end-stage renal disease (ESRD). In recent
studies in ESRD, we found that UTN is inversely, rather than
directly, related with cardiovascular stress hormones such as
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norepinephrine and plasma brain natriuretic peptide,18 and
that high plasma levels of this peptide predict better clinical
outcomes, that is reduced cardiovascular complications, in
this population.11 To explore further the implications of
raised UTN in renal diseases, we have now extended our
observations to a well-characterized, incident cohort of stage
2–5 CKD patients. In this cohort, we performed a detailed
analysis of the relationship between UTN with death and fatal
cardiovascular events. The results of this study indicate that
high UTN levels signals a situation of relatively lower risk for
death and atherosclerotic complications in these patients.
RESULTS
Patient characteristics
Table 1 presents the demographic and the baseline charac-
teristics of the study cohort. At enrollment, the study
population had an average age of 71711 years, 64% of the
patients were male, 24% had diabetes, and 58% had
background cardiovascular complications. Baseline glomeru-
lar filtration rate (GFR) was 31715 ml min1 per 1.73 m2,
and serum creatinine was 2.471.2 mg dl1. In this cohort,
plasma UTN (median 4.4 ng ml1, interquartile range:
2.0–7.4 ng ml1) was significantly higher (Po0.01) than that
in healthy subjects (median 2.8 ng ml1, interquartile range:
1.9–4.6 ng ml1), but did not differ significantly by diabetic
status (P¼ 0.255).
Correlates of UTN and multiple linear regression model
At univariate analysis, plasma UTN was related inversely to
age (r¼0.18, P¼ 0.04), history of coronary artery disease
(r¼0.28, P¼ 0.002) and serum C-reactive protein (CRP;
r¼0.21, P¼ 0.02) and directly to serum albumin (r¼ 0.37,
Po0.001), male sex (r¼ 0.22, P¼ 0.02), and serum creati-
nine (r¼ 0.18, P¼ 0.04). No association was found between
plasma UTN and GFR (r¼0.01, P¼ 0.87), as well as
between UTN and the remaining risk factors listed in Table 1.
After adjustment for all univariate correlates of plasma UTN,
only serum albumin (b¼ 0.26, P¼ 0.004) and history of
coronary artery disease (b¼0.22, P¼ 0.01) maintained an
independent association with plasma UTN (Table 2). In this
multiple regression model, due to the collinearity between
history of coronary artery disease and serum albumin with
serum CRP (r¼ 0.30, P¼ 0.001 and r¼0.24, P¼ 0.006,
respectively), this latter variable failed to correlate signifi-
cantly with plasma UTN. Serum CRP becomes a significant
correlate of plasma UTN (b¼0.18, P¼ 0.05) only when
history of coronary artery disease and serum albumin were
excluded from the model.
Survival data
During the study period (mean follow-up 41 months;
median 48, range 3.4–60), 43 patients died (29 for
cardiovascular events, 8 for malignancies or cachexia, and 6
for infectious diseases); 29 subjects started dialysis and 13
had a reduction of GFR to values lower than half of their
baseline measures. Table 3 summarizes the unadjusted hazard
ratios for death from all causes associated with UTN and
other considered risk factors. In this crude analysis, UTN,
acute phase reactive proteins (serum albumin, CRP, and
fibrinogen), baseline GFR and proteinuria, update values of
GFR over time or progression to ESRD, and complications of
CKD such as anemia as well as previous history of coronary
artery disease were associated with adverse outcomes,
whereas remaining variables in Table 1 were not. Other
comorbid conditions, including diabetes and neoplasm, and
current specific and multiple treatments were not found to be
significantly associated with death.
An initial model was built on age, baseline GFR and
proteinuria, UTN, and CRP. The use of updated rather
than baseline GFR values improved the model fit, whereas
history of coronary artery disease replaced age (those with
Table 1 | Main demographic, somato-metric, clinical, and
biochemical parameters of the study population
Age (year) 71.0711.0
BMI (kg m2) 26.674.7 (425 in 74
patients (61%))
Male sex no. (%) 78 (64%)
Diabetics no. (%) 29 (24%)
Presence of any cardiovascular
disease (%)
75 (61%)
Patients with coronary artery
disease no. (%)
44 (36%)
Patients with peripheral vascular
disease no. (%)
34 (28%)
Patients with cerebro-vascular
disease no. (%)
31 (25%)
Patients with heart failure no. (%) 34 (28%)
Systolic pressure (mm Hg) 139.8714.0 (4140 in 37
patients (30%))
Diastolic pressure (mm Hg) 81.177.6 (490 in 7 patients
(6%))
Albumin (g dl1) 3.970.6 (o4 in 72 patients
(59%))
Calcium (mg dl1) 9.470.7
(o8.8 in 13 patients (11%))
(410.2 in 6 patients (5%))
Phosphate (mg dl1) 3.470.8
(o2.5 in 8 patients (7%))
(45.0 in 5 patients (4%))
Hemoglobin (g dl1) 12.871.5
(Females: o12.0 in 20
patients (45%))
(Males: o13.6 in 46 patients
(59%))
Cholesterol (mg dl1) 209749 (4265 in 16
patients (13%))
HDL (mg dl1) 53713 (o30 in 0 patient)
Triglycerides (mg dl1) 134 (105–190) (4160 in 45
patients (37%))
CRP (mg l1) 4.7 (1.4–10.1) (43 in 79
patients (65%))
Homocysteine (mmol l1) 23.7 (17.8–31.4) (415 in 102
patients (84%))
Uric acid (mg dl1) 6.972.2 (47 in 47 patients
(38%))
UTN (ng ml1) 5.073.6
Urinary protein (mg per 24 h) 20 (absolute range 2–724)
BMI, body mass index; CRP, C-reactive protein; HDL, high-density lipoprotein; UTN,
urotensin II.
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pre-existing cardiovascular disease were significantly older).
When progression to ESRD was introduced into the model in
place of baseline or updated GFR values, the fit improved
significantly and proteinuria lost any predicting power.
Finally, serum albumin had a borderline significant effect
(hazard ratio: 0.67; 95% confidence intervals 0.40 and 1.13)
only if UTN was excluded from the model but had no effect
in presence of UTN. Importantly, in the final model
(Figure 1), increased UTN levels predicted lower risk for
event occurrence (about 10% less per 1 ng ml1 increase in
plasma level), independent of all other measured covariates at
any step of the model building process. Adjusted differences
in overall survival by quartile-defined categories are described
in Figure 2. Both final models of mortality from all causes
and cardiovascular events are adjusted for previous history
coronary artery disease, CRP, and the effect of progression to
halving GFR or dialysis. The parameter estimates of UTN are
materially the same in the two models (Figure 1), although
the model of cardiovascular death is ‘over-parametrized’ (i.e.,
too many variables for the event number). Remarkably, in
these multiple Cox regression models, the explained variation
in both all-cause and cardiovascular mortality attributable to
plasma UTN was 5.3 and 6.5%, respectively. None of the
remaining risk factors, including comorbid conditions, blood
pressure values (systolic, diastolic, and pulse pressure), and
antihypertensive drugs, fibrinogen, calcium, phosphate, and
calcium–phosphate product had any significant effect or
modified the estimates of the covariates of the final model.
DISCUSSION
Study findings
This study shows that UTN is increased in patients with 2–5
CKD and shows that in this population, plasma UTN is an
inverse predictor of death and cardiovascular events.
UTN and the cardiovascular system
The role of UTN in human diseases is much controversial.
This peptide was initially touted as the ‘most potent
mammalian vasoconstrictor to date’.1 The presence and the
action of UTN in the cardiovascular system and in the kidney
are being intensely investigated. UTN is overexpressed in
human cardiomyocytes and vascular smooth muscle cells of
patients with advanced heart failure,7 and circulating levels in
these patients are related with big endothelin-1 and with
brain natriuretic peptide,19 that is two peptides involved in
cardio-circulatory control in this condition. Although UTN
is currently held as a potential target for intervention in
cardiovascular and renal diseases, the plasma concentration
of this peptide has been recently found to be reduced rather
than increased in acute coronary syndromes,20 whereas
relatively higher UTN levels predicted a better outcome in
patients with myocardial infarction.21
UTN and the kidney
The kidney is a major source of UTN in mammals. The
parent compound pre–pro UTN is highly expressed in human
kidneys.22 UTN is present in endothelial and smooth muscle
cells of renal vessels23 as well as in the tubular cells and it is
excreted in the urine at concentrations far superior to those
typically found in plasma.24 The kidney actively synthesizes
UTN because studies in the sheep revealed that in this ovine,
the kidney as well as the lung and the liver actively secrete
UTN into the systemic circulation.25 Thus, similarly to other
autacoids, UTN may also act as a circulating hormone.
Plasma UTN is much increased in renal diseases including
minimal change glomerulopathy with normal GFR,26 dia-
betic nephropathy at a stage of normal renal function and
Table 2 | Multiple linear regression of plasma UTN
Units of measure b s.e. b P-value
Albumin 1 g dl1 1.666 0.5560 0.26 0.004
CAD 0=No; 1=Yes 1.660 0.656 0.22 0.01
Sex 0=F; 1=M 1.130 0.651 0.15 0.09
Creatinine 1 mg dl1 0.306 0.256 0.10 0.23
CRP (log10) 1 logarithmic unit 0.295 0.408 0.07 0.47
Age Years 0.017 0.028 0.05 0.55
b, regression coefficient; b, standardized regression coefficient; CAD, coronary artery disease; CRP, C-reactive protein; F, female; M, male; s.e., standard error.
Multiple R=0.48.
Constant: 1.005, s.e.: 3.064.
Table 3 | Unadjusted HRs for death (HR, with 95% CIs)
associated with UTN and other traditional and nontraditional
cardiovascular risk factors
Variable HR 95% CI P-value
UTN (1 ng ml1) 0.90 0.82, 0.99 0.035
CRP (mg dl) 1.02 1.01, 1.03 o0.001
Albumin (g dl) 0.57 0.35, 0.94 0.027
Fibrinogen (100 mg dl) 1.32 1.06, 1.64 0.011
Proteinuria (g l) 1.25 1.06, 1.49 0.008
Baseline GFR (ml per min
per 1.73 m2)
0.97 0.95, 0.99 0.027
Updated GFR (ml per
min per 1.73 m2)
0.96 0.94, 0.98 0.012
Progression to ESRD 2.77 1.44, 5.34 0.002
Hemoglobin (g dl1) 0.71 0.57, 0.87 0.002
History of coronary
artery disease
3.03 1.44, 6.37 0.003
Age (per year) 1.04 1.01, 1.07 0.008
Gender (male vs female) 0.74 0.40, 1.36 0.337
CRP, C-reactive protein; CI, confidence interval; ESRD, end-stage renal disease; GFR,
glomerular filtration rate; HR, hazard ratio; UTN, urotensin II.
The HR refers to one unit increase of each variable.
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independent of proteinuria,10 and at a stage of moderate-to-
severe CKD27 and in ESRD.11,12 Contrarily to our expecta-
tions, in previous studies in ESRD patients, we found that
plasma levels of this peptide correlated inversely with
sympathetic activity and brain natriuretic peptide,18 with
biomarkers of inflammation as well as with background
cardiovascular risk.28 These observations suggested to us that
high UTN may signal a cardio-vasculo-protective state in this
population. Coherently, the results of a recent prospective
cohort study supported the hypothesis generated from cross-
sectional analyses because UTN was an inverse predictor of
fatal and non-fatal cardiovascular events in this population.11
UTN and CKDs
Extending clinical observations on UTN to CKD is of
obvious importance because this is a much larger population
with a risk of death and cardiovascular complications by far
lower than that seen in ESRD patients.29 Testing the
prediction power of plasma levels of this substance in stable
patients with CKD may provide new clues for understanding
the implication of this peptide in a larger disease spectrum
and across a wide range of renal function loss. The incident
cohort enrolled into this study had an age range which is
typical of patients presently being followed up in nephrology
clinics in most western countries.30 As with ESRD patients,
we found that UTN was associated directly with serum
albumin, that is a strong inverse marker of nutrition and
inflammation, and inversely with age. Importantly, UTN was
largely independent of established risk factors for death and
cardiovascular events, such as blood pressure, GFR level,
proteinuria, and other nontraditional risk factors such as
hemoglobin and homocysteine. The fact that UTN was
unrelated to GFR may indicate that the plasma concentration
of this substance increases at an early stage of renal
impairment and that it remains relatively constant through-
out the evolution of renal disease, a possibility in keeping
with previous observations in minimal change disease26 and
in diabetic nephropathy.10,27 At baseline, UTN was higher in
patients with a history of coronary artery disease than in
those without suggesting that high levels of this peptide
underlie a situation of relatively lower risk. Such a hypothesis
was again confirmed by the prospective observation because
patients with relatively higher UTN values had a longer
survival and a lower incidence of cardiovascular events than
those with relatively lower values with a clear inverse
dose–response relationship between UTN levels and adverse
outcomes. Notably, these associations cannot be attributed to
concomitant disease such as acute cardiac ischemia or heart
failure because stable CKD patients without intercurrent
clinical problems composed our cohort.
Interpretation
Two explanations can be advanced to explain why high UTN
may be a marker of lower risk in patients with CKD. First,
low UTN in CKD may reflect wasting and malnutrition, a
hypothesis suggested by the direct association of UTN with
albumin and serum creatinine (independent of the GFR). In
our study, the predictive power of UTN for all cause and
cardiovascular death was largely independent of BMI,
albumin, past cardiovascular events, progression to ESRD,
CRP, and other potential confounders. However, given the
strong relationship between nutritional status and clinical
outcomes in CKD,31 it still remains possible that the link
between UTN and adverse clinical outcomes be the result of
inadequate adjustment for the effect of malnutrition
(residual confounding). Alternatively, it can be hypothesized
that high UTN interferes with mechanism(s) of organ
damage in CKD patients. As alluded to before, UTN is
expressed in endothelial cells and behaves as a potent
endothelium-dependent vasodilator in human pulmonary
and abdominal resistance arteries,13 an effect likely attribu-
table to the release of nitric oxide as well as of endothelium
hyperpolarizing factor.32 Endothelial dysfunction is pervasive
Mortality from all causes
Mortality from CV events
UTN (ng dl–1), HR 0.89 (0.81, 0.97)
UTN (ng dl–1), HR 0.88 (0.8, 0.97)
CRP (mg dl–1), HR 1.02 (1.01, 1.03)
CRP (mg dl–1), HR 1.02 (1.01, 1.04)
P-ESRD (Y/N), HR 3.98 (2, 7.93)
P-ESRD (Y/N), HR 4.09 (1.76, 9.46)
CVD (Y/N), HR 2.9 (1.38, 6.1)
CVD (Y/N), HR 5.04 (1.75, 14.4)
1.00 1.58 2.51
Hazard ratio (log scale)
3.98 6.31 10.00 15.9
Figure 1 | Final Cox’s models of (a) overall mortality (event
number¼ 43); (b) cardiovascular mortality (event number¼ 29).
Variables in each model are reported with the associated hazard
ratios (HRs, with 95% confidence intervals, CIs). Both models are
independent of age, gender, baseline GFR and proteinuria, and other
clinical characteristics and traditional and nontraditional
cardiovascular risk factors (see text). The HR refers to one unit
increase of each covariate.
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Figure 2 | Estimated survival probability by quartiles of plasma
UTN. The curves are adjusted for history of coronary artery disease,
CRP, and progression to ESRD.
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in CKD and it is possible that the inverse relationship
between UTN and adverse clinical outcomes be the expres-
sion of an UTN-driven counter-regulatory response aimed
at restoring endothelial function. In this regard, it is
important noting that UTN is inversely related with the
endogenous inhibitor of NOS asymmetric dimethyl-arginine
in ESRD.28
Strengths and limitations
It was emphasized that methods of measurement of UTN are
still too variable.3 Our assay was well standardized and the
antibody we used did not crossreact with pre–pro UTN and
UTN-like peptide, whereas it crossreacted with truncated
human U-II analogs such as [4–11] human UTN and [5–11]
UTN which are equipotent agonists at the UTN receptors
compared with mature UTN. Furthermore, inverse relation-
ships between UTN and adverse outcomes were also found in
a study in patients with heart failure employing an antibody
different from that we used in this study.21 Undoubtedly, the
purely observational design is an objective limitation of this
study and any causal inference drawn from the data remains a
hypothesis to be tested in further studies.
Conclusion
At present no firm conclusion can be reached on whether and
how this peptide interferes with the pathophysiological
mechanism(s) leading to adverse outcomes. This is especially
important because UTN antagonists are being developed and
one of these is being tested in patients with diabetic
nephropathy.33 Preliminary results of short-term studies
(2 weeks) indicate that UTN antagonism is well tolerated.
However, we believe that at this stage of knowledge,
mechanistic insights are still needed before launching long-
term interventional studies based on solid outcome measures
such as death and cardiovascular events in patients with
CKD.
MATERIALS AND METHODS
Study protocol, inception cohort assembled, and referral
pattern
This cohort study was designed specifically to investigate the impact
of nontraditional cardiovascular risk factors on patient outcomes in
CKD stages 2–5. The protocol was in conformity to the Declaration
of Helsinki Principles and informed consent was obtained from each
participant at enrollment.
All consecutive patients who were referred to the outpatient
clinic of the Division of Nephrology at Cremona Hospital from
January 2002 to April 2003 were recruited. This hospital is a tertiary
care hospital serving a population of approximately 200 000
residents. Patients had to be referred for the first time to the
nephrologist and receive a diagnosis of CKD stages 2–5 without
imminent need for dialysis commencement.
Baseline data and laboratory measurements
Data on baseline characteristics, previous or actual smoking
habit, documented diagnosis of renal disease causes, diabetes,
cardiovascular disease (ictus, transient ischemic attack, clinical
peripheral artery disease, angina or myocardial infarction, heart
failure – New York Heart Association (NYHA) class II or greater),
chronic lung disease, neoplasm, and history of hypertension (absent,
o5 years, 5–10, 10–20, and greater than 20 years) were collected at
the first referral and defined on the basis of the diagnosis-related
group classification and International Classification of Diseases,
Ninth Revision.
Blood pressure was measured three times (at 2- to 5-min
intervals with a mercury sphygmomanometer), and the average
value was considered for data analysis. Drug prescriptions were
recorded accurately. Recordings included the use of calcium channel
blockers, a- and b-blockers, diuretics, converting enzyme inhibitors,
angiotensin receptors and aldosterone antagonists, statins, erythro-
poietins and darbopoietin, antiplatelet agents, digoxin, anti-
arrhythmic drugs, nitro-derivatives, anticoagulants, anti-diabetic
agents, vitamins and calcium supplements. All patients were in
stable clinical conditions and none had acute coronary syndrome or
evidence of cardiovascular congestion at the time of enrollment.
All patients were instructed carefully for 24-h urine collection
and additional urine spot for proteinuria assessment. Blood
sampling was performed, after an overnight fast, between 0700
and 0900 hours. After 20–30 min of quiet resting in semi-recumbent
position, samples were taken into chilled ethylenediaminetetraacetic
acid vacutainers, placed immediately on ice, centrifuged within
30 min at 411C, and the plasma stored at 801C until assay.
A sample for serum lipids, creatinine, uric acid, albumin, calcium
and phosphate, CRP, total homocysteine (Hcy), and hemoglobin
was obtained from all patients at baseline. Serum cholesterol,
albumin, calcium, and phosphate measurements were made using
standard methods in the routine clinical laboratory. GFR was
estimated using the four-variable Modification of Diet in Renal
Disease formula.34 Plasma total Hcy (Abbott Laboratories, Berk-
shire, UK) and serum CRP (Behring, Scoppito, L’Aquila, Italy) were
measured by using commercially available kits.
UTN was determined by a high-sensitivity enzyme immunoassay
employing an antibody (Phoenix Pharmaceuticals, Belmont, CA,
USA), which does not crossreact with endothelin-1, angiotensin II,
adrenomedullin, calcitonin-gene-related peptide, and brain na-
triuretic peptide. Furthermore, investigations specifically related to
this study were performed at Phoenix Laboratories to test the
crossreactivity of this antibody with human pre–pro UTN (10–125),
UTN-related peptide as well as with UTN (4–11) and (5–11)
fragments. These additional studies showed no crossreactivity (0%)
with pre–pro UTN, 19.8% crossreactivity with UTN-related peptide
and 15 and 22% crossreactivity with UTN (84–11) and (5–11)
fragments. The intra-assay coefficient of variation was 12% and all
samples were processed in a single assay. Plasma UTN was also
measured in a group of 103 normotensive healthy subjects with
normal serum creatinine matched to CKD patients as for age
(average age: 70 years) and gender (67 men and 36 women). These
subjects were mainly recruited from healthy blood donors in our
hospital and all had a GFR 480 ml min1.
Follow-up data
Patients were followed regularly with frequency dependent on renal
function and comorbid conditions. After the initial assessments,
laboratory and clinical data that included cardiovascular events and
death, renal function deterioration, and the need for dialysis as a
result of ESRD were recorded accurately. For avoiding loss to follow-
up, patients were contacted by telephone in case they missed any
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appointment and at the study end date (15 December 15 2006) if
their last scheduled visit was before December 2006 and if they were
not known to be already on dialysis or died. Each death was
reviewed and assigned an underlying cause by three physicians not
involved in the study, on the basis of all available medical
information. In cases of out-of-hospital deaths, family members
and the general practitioner were interviewed by telephone to
ascertain the circumstances surrounding the death.
Statistical analyses
Data are expressed as mean7s.d., median and interquartile range,
or frequencies, as appropriate. Variables who deviated from the
normal distribution (positively skewed) were log-transformed
(log10) before the correlation study.
General linear model of UTN: plasma UTN was modeled as a
function of a series of traditional and nontraditional risk factors for
renal dysfunction (including clinical data and laboratory measures
described above) and GFR on the basis of their univariate
association or clinical plausibility. Data are expressed as correlation
coefficients (r), regression coefficients (b), standardized regression
coefficients (b), and P-values.
Survival functions: the Cox procedure was used to model time-
to-patient death (from all or cardiovascular causes) as a function of
UTN levels controlling for the effect of baseline clinical characteris-
tics and comorbid conditions. The effect of renal function decline
on patient mortality was tested using updated GFR values over time
(time-varying GFR values) and creating a time-varying covariate
indicating progression to a 50% reduction of baseline GFR values or
ESRD requiring dialysis (progressed to ESRD vs never/not yet
progressed). In this extended Cox’s model, a robust variance–
covariance matrix of the estimators was used to account for multiple
observations per subjects (more GFR measurements or pre-ESRD
and post-ESRD status). Covariates that were considered to develop
the survival model included all traditional and emerging risk factors
described previously. The largest possible meaningful model
considered included clinically consistent variables and interpretable
interaction terms identified on the basis of biologic plausibility or
strength of their univariate relation to the outcome, following the
rule of 10 (one parameter per 10 events) and considering the overall
model fit and hazard proportionality. A manual hierarchical
elimination approach was followed, monitoring variations of the
exposure regression coefficient to identify variables that were eligible
to be dropped as non-confounders. The contribution of the
covariates to explain the dependent variable was assessed by means
of a two-tailed Wald test, with Po0.05 considered significant. The
explained variation in all-cause and cardiovascular mortality
attributable to plasma UTN was calculated by using the 2 log
likelihood statistics in multiple Cox regression models.35 Model
specification and overall fit were checked by re-estimation, formal
and graphical tests based on residuals, and testing the interaction
with time of the variables in the model. Analyses were performed
using STATA 9.2 SE (Stata Corp., College Station, TX, USA).
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